Cargando…
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
INTRODUCTION: Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating the need for combination therapy. METHODS AND RESU...
Autores principales: | Eleveld, Thomas F., Vernooij, Lindy, Schild, Linda, Koopmans, Bianca, Alles, Lindy K., Ebus, Marli E., Dandis, Rana, van Tinteren, Harm, Caron, Huib N., Koster, Jan, van Noesel, Max M., Tytgat, Godelieve A. M., Eising, Selma, Versteeg, Rogier, Dolman, M. Emmy M., Molenaar, Jan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990464/ https://www.ncbi.nlm.nih.gov/pubmed/36895472 http://dx.doi.org/10.3389/fonc.2023.1130034 |
Ejemplares similares
-
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022) -
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma
por: van den Boogaard, Marlinde L., et al.
Publicado: (2021) -
DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells
por: Dolman, M. Emmy M., et al.
Publicado: (2015) -
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016) -
The potential of PARP as a therapeutic target across pediatric solid malignancies
por: Keller, Kaylee M., et al.
Publicado: (2023)